360 related articles for article (PubMed ID: 7228576)
1. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
Kalland T; Haukaas S
Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
[TBL] [Abstract][Full Text] [Related]
2. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
Benson RC; Cummings K
Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
[No Abstract] [Full Text] [Related]
3. [Clinical study of estramustine phosphate (Estracyt) on prostatic cancer].
Murase T; Mitsuya H; Honda N; Fukatu H; Aota Y; Shinoda M; Yoshida K; Sobajima T; Ohishi M; Tsumura Y
Hinyokika Kiyo; 1989 Jan; 35(1):179-85. PubMed ID: 2729015
[TBL] [Abstract][Full Text] [Related]
4. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
Hauchecorne J
Prog Clin Biol Res; 1987; 243B():229-34. PubMed ID: 3309983
[No Abstract] [Full Text] [Related]
5. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
Nickel CJ; Morales A
Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
[TBL] [Abstract][Full Text] [Related]
6. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
[TBL] [Abstract][Full Text] [Related]
7. Treatment of prostatic carcinoma with estramustine phosphate (Estracyt).
Benson RC
Wis Med J; 1976 Sep; 75(9):S89-90. PubMed ID: 969557
[No Abstract] [Full Text] [Related]
8. Immunological effects of diethylstilbestrol and estramustine phosphate.
Haukaas SA
Scand J Urol Nephrol Suppl; 1984; 83():1-32. PubMed ID: 6387896
[No Abstract] [Full Text] [Related]
9. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
[TBL] [Abstract][Full Text] [Related]
10. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
Murphy GP; Slack NH; Mittelman A
Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
[No Abstract] [Full Text] [Related]
11. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.
Hedlund PO; Gustafson H; Sjögren S
Scand J Urol Nephrol Suppl; 1980; 55():103-5. PubMed ID: 6938012
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of hormone-resistant prostate cancer with estramustine phosphate (Estracyt)].
Stridsklev IC; Fosså SD; Kaalhus O
Tidsskr Nor Laegeforen; 1984 Oct; 104(28):1977-80. PubMed ID: 6388019
[No Abstract] [Full Text] [Related]
13. [Clinical studies on serum lipids in the patients with tumor of the prostate gland. 2nd. Report. Changes of serum lipids and lipoprotein fractions during the treatment of estramustine phosphate disodium, hexestrol and diethylstilbestrol 4, 4-diphosphoric ester for the patients with prostatic cancer (author's transl)].
Yoshida H; Shimada M
Nihon Hinyokika Gakkai Zasshi; 1980 Jan; 71(1):59-69. PubMed ID: 6155501
[TBL] [Abstract][Full Text] [Related]
14. Estramustine for prostate cancer.
Med Lett Drugs Ther; 1982 Aug; 24(615):74. PubMed ID: 7099111
[No Abstract] [Full Text] [Related]
15. [Treatment of advanced carcinoma of the prostate with estramustine phosphate (estracyt)].
Lancina Martín JA; Chantada Abal V; Lamas Meilan AC; González Martín M
Actas Urol Esp; 1984; 8(5):399-402. PubMed ID: 6524487
[No Abstract] [Full Text] [Related]
16. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
[TBL] [Abstract][Full Text] [Related]
17. [Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].
Daponte DP; Stevens I; Robinson MR
Actas Urol Esp; 1986; 10(6):437-40. PubMed ID: 3825644
[No Abstract] [Full Text] [Related]
18. The EORTC Phase III trials in prostatic cancer.
Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
[No Abstract] [Full Text] [Related]
19. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
Smith PH; Suciu S; Robinson MR; Richards B; Bastable JR; Glashan RW; Bouffioux C; Lardennois B; Williams RE; de Pauw M
J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
[TBL] [Abstract][Full Text] [Related]
20. [Predictive value of clinical, biochemical, hormonal and histologic parameters of the endocrine response in prostatic adenocarcinoma].
Burgos FJ; Maganto E; Jiménez M; Mayayo T; Allona A; Mateos A; Escudero A; Romero-Aguirre C
Actas Urol Esp; 1988; 12(6):500-6. PubMed ID: 3232555
[No Abstract] [Full Text] [Related]
[Next] [New Search]
